so SPL7013 has current identified markets of
- BV treatment 750 mil US
- BV prevention 1,000 mil US
- viral conjunctivitis 700 mil US
- condom coatings. pfff nil to negligible in my view (the market / consumer doesn't value it at present)
unmet medical needs in the first 3 cases (although antibiotics are available for BV treatment, but clearly not preferred).
I hope they partner early for the conjunctivitis trials. they have already stated they can leverage some of the existing clinical data and if they choose the right partner the path to market for this could be a lot quicker than many anticipate. No doubt early payment milestones would also be a feature. only recently a colleague of mine had viral conjunctivitis and was lamenting how the doctors could do nothing for him.
come on Jackie, let's get this US license deal done! FDA approval will occur before we know it as well.
so SPL7013 has current identified markets of - BV treatment 750...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
